Tempus AI (NASDAQ:TEM) Stock Price Down 5.7% – Time to Sell?

Tempus AI, Inc. (NASDAQ:TEM)’s stock price traded down 5.7% on Friday. The company traded as low as $67.13 and last traded at $67.0680. 1,330,559 shares were traded during mid-day trading, a decline of 79% from the average session volume of 6,199,571 shares. The stock had previously closed at $71.13.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Canaccord Genuity Group raised their price objective on shares of Tempus AI from $80.00 to $95.00 and gave the stock a “buy” rating in a report on Monday. Guggenheim raised their price objective on shares of Tempus AI from $65.00 to $92.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Lake Street Capital downgraded shares of Tempus AI to a “hold” rating in a research note on Monday, July 20th. Wall Street Zen raised Tempus AI from a “sell” rating to a “hold” rating in a research report on Saturday, July 25th. Finally, Piper Sandler raised shares of Tempus AI from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $56.00 to $76.00 in a research report on Tuesday, September 1st. Eleven research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Tempus AI has a consensus rating of “Hold” and an average target price of $72.37.

Tempus AI Trading Down 6.6%

The stock has a market cap of $11.99 billion, a price-to-earnings ratio of -46.19 and a beta of 3.54. The business has a 50-day simple moving average of $67.81 and a two-hundred day simple moving average of $56.43. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. The firm had revenue of $382.49 million during the quarter, compared to analysts’ expectations of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The company’s revenue for the quarter was up 21.6% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.22) earnings per share. Equities analysts forecast that Tempus AI, Inc. will post -1.38 EPS for the current fiscal year.

Insiders Place Their Bets

In other Tempus AI news, CAO Ryan Bartolucci sold 7,062 shares of Tempus AI stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $75.00, for a total value of $529,650.00. Following the completion of the transaction, the chief accounting officer directly owned 60,804 shares of the company’s stock, valued at $4,560,300. The trade was a 10.41% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Ryan Fukushima sold 700 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $70.00, for a total transaction of $49,000.00. Following the completion of the transaction, the chief executive officer directly owned 15,874 shares in the company, valued at approximately $1,111,180. This represents a 4.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,280,965 shares of company stock valued at $80,397,564 in the last quarter. Company insiders own 24.26% of the company’s stock.

Hedge Funds Weigh In On Tempus AI

Several large investors have recently modified their holdings of TEM. V Square Quantitative Management LLC bought a new stake in shares of Tempus AI in the 3rd quarter valued at about $27,000. Arkadios Wealth Advisors boosted its position in Tempus AI by 9.6% during the first quarter. Arkadios Wealth Advisors now owns 4,963 shares of the company’s stock valued at $224,000 after purchasing an additional 435 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Tempus AI by 54.3% during the third quarter. GAMMA Investing LLC now owns 1,239 shares of the company’s stock valued at $101,000 after buying an additional 436 shares during the last quarter. EMC Capital Management bought a new stake in shares of Tempus AI in the 2nd quarter valued at about $29,000. Finally, Ulland Investment Advisors LLC bought a new position in shares of Tempus AI during the 3rd quarter worth approximately $41,000. Institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI, Inc is a technology company focused on applying artificial intelligence and data analytics to precision medicine. The company develops tools intended to help physicians make more informed treatment decisions by combining clinical information, molecular data and other health-related datasets.

Tempus provides genomic testing and diagnostic services, including sequencing and other molecular tests used primarily in oncology. Its platform also offers data and software solutions designed to support clinical research, pharmaceutical development, patient identification for clinical trials and the development of personalized treatment strategies.

Founded in 2015, Tempus is headquartered in Chicago and primarily serves healthcare providers, researchers and life sciences companies.